Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Retained Earnings (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Retained Earnings for 8 consecutive years, with -$330.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 4.97% to -$330.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$330.0 million, a 4.97% decrease, with the full-year FY2024 number at $16000.0, down 40.74% from a year prior.
  • Retained Earnings was -$330.0 million for Q3 2025 at Whitehawk Therapeutics, down from -$312.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $27000.0 in Q4 2023 to a low of -$330.0 million in Q3 2025.
  • A 5-year average of -$160.9 million and a median of -$165.7 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: surged 100.01% in 2023, then plummeted 1964781.25% in 2024.
  • Whitehawk Therapeutics' Retained Earnings stood at -$126.7 million in 2021, then crashed by 60.38% to -$203.2 million in 2022, then soared by 100.01% to $27000.0 in 2023, then crashed by 40.74% to $16000.0 in 2024, then tumbled by 2062600.0% to -$330.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Retained Earnings are -$330.0 million (Q3 2025), -$312.3 million (Q2 2025), and -$259.6 million (Q1 2025).